Tag: Darmstadt

Increasing the efficacy of monoclonal antibodies

Written by
Dr Martina Zimmerman has used ThioFuc as part of the cell culture media in order to improve the potency of rituximab, which may in turn lead to a reduction in the number of antibody treatments required

The advent of monoclonal antibody (mAb) technology has allowed the production of antibodies that can target specific antigens on malignant tumour cells or other inflammatory molecules that are known to exacerbate diseases such as rheumatoid arthritis or Crohn’s disease. Dr Martina Zimmermann, Dr Aline Zimmer, and their team from Merck KGaA, Darmstadt, Germany, added 5-Thio-L-Fucose (ThioFuc) to the cell culture […]

Read More… from Increasing the efficacy of monoclonal antibodies